Table 1.
Distribution of cohort: IECC subtypes, patient age, tumor size, FIGO stage, presence of LVI, LNM, and local (pelvic) and distant (extrapelvic) recurrences
| Subtypes | Cases nr/% | Age* (IQR) | Tumor size* (mm) (IQR) | FIGO stage I nr/% | FIGO stage II nr/% | FIGO stage III nr/% | FIGO stage IV nr/% | LVI nr/% | LNM nr/% | Local recurrence nr/% | Distant recurrence nr/% |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Usual (HPVA) | 147 (71.7) | 42 (16–82) | 20 (1–144) | 123 (83.7) | 7 (4.76) | 2 (1.36) | 1 (0.68) | 73 (49.8) | 18 (12.2) | 13 (8.8) | 8 (5.4) |
| Mucinous NOS (HPVA) | 3 (1.46) | 41 (41–44) | 6 (6–21) | 2 (66.7) | 1 (33.3) | 0 | 0 | 2 (66.7) | 0 | 1 (33.3) | 0 |
| Mucinous Intestinal (HPVA) | 4 (1.95) | 37.5 (30–67) | 8.5 (0.5–1.5) | 3 (75) | 1 (25) | 0 | 0 | 0 | 0 | 1 (25) | 0 |
| iSMILE (HPVA) | 9 (4.39) | 50 (25–66) | 9 (3–36) | 8 (88.9) | 0 | 1 (11.1) | 0 | 2 (22.2) | 2 (22.2) | 0 | 2 (22.2) |
| Villoglandular (HPVA) | 2 (0.97) | 31 (31–31) | 6 (4–8) | 2 (100) | 0 | 0 | 0 | 2 (100) | 2 (100) | 0 | 0 |
| Adenocarcinoma NOS (HPVA) | 4 (1.95) | 57 (35–68) | 38.5 (15–45) | 0 | 0 | 4 (100) | 0 | 2 (50) | 2 (50) | 0 | 2 (50) |
| Gastric (NHPVA) | 24 (11.7) | 49.5 (36–78) | 40 (10–90) | 9 (37.5) | 11 (45.8) | 2 (8.33) | 0 | 20 (83.3) | 4 (16.7) | 8 (33.3) | 2 (8.33) |
| Clear cell (NHPVA) | 7 (3.41) | 65 (33–79) | 43 (5.5–45) | 4 (57.1) | 3 (42.9) | 0 | 0 | 5 (71.4) | 1 (14.3) | 0 | 3 (42.9) |
| Endometrioid (NHPVA) | 2 (0.97) | 60.5 (55–65) | 17.2 (4.3–30) | 1 (50) | 0 | 0 | 0 | 1 (50) | 1 (50) | 0 | 0 |
| Serous (NHPVA) | 1 (0.48) | 69 | 44 | 0 | 1 (100) | 0 | 0 | 1 (100) | 1 (100) | 0 | 1 (100) |
| Mesonephric (NHPVA) | 1 (0.48) | 52 | 0.2 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adenocarcinoma NOS (NHPVA) | 1 (0.48) | 64 | 35 | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 |
*
Median
Abbreviations: nr, number of cases; %, percentage of cases; LVI, lymphovascular invasion; LNM, lymph node metastases